• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Lexacalcitol Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755095

Lexacalcitol is over 100 times more active than 1alpha,25-dihydroxyvitamin D3 [1alpha,25-(OH)2D3], as judged by in vitro antiproliferative and cell differentiating assays. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Lexacalcitol, Inhibitor
Full Product Name
Lexacalcitol
Product Synonym Names
KH1060
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
460.69
Solubility
<1mg/ml refers to the product slightly soluble or insoluble
Formula
C29H48O4
SMILES
C[C@]1(CCC/2)[C@](CC[C@@H]1[C@@H](C)OCCCC(CC)(CC)O)([H])C2=C\C=C(C[C@@H](O)C[C@@H]3O)/C3=C
CAS Number
131875-08-6
Target & IC50
Others
In Vitro
KH1060 was not an effective competitor of C24 oxidation of 1alpha,25-(OH)2D3. KH 1060 inhibited PBMC proliferation and decreased TNF-alpha levels in IBD patients and this effect was synergistic with anti-TNF-alpha. KH1060 metabolism could be blocked by the cytochrome P450 inhibitor, ketoconazole. Certain hydroxylated metabolites of KH1060 retained significant biological activity in vitamin D-dependent reporter gene systems. VDR protein levels were significantly increased by PBMC treatment with KH 1060 or anti-TNF-alpha or their combination in ulcerative colitis (UC) patients, and decreased in Crohn's disease (CD) patients, treating the cells with KH 1060. A synergistic inhibition was registered combining KH 1060 and anti-TNF, at well-defined concentrations. 0.1nM KH 1060 produced a significant decrease in TNF-alpha levels, determined by ELISA, although less remarkable than in the presence of anti-TNF.

Product References and Citations for Lexacalcitol, inhibitor

Dilworth FJ, et al. The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity.Endocrinology. 1997 Dec;138(12):5485-96.
Dilworth FJ, et al. The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity.Endocrinology. 1997 Dec;138(12):5485-96.
Fullerton A, et al. Characterization of irritant patch test reactions to topical D vitamins and all-trans retinoic acid in comparison with sodium lauryl sulphate. Evaluation by clinical scoring and multiparametric non-invasive measuring techniques. Br J Dermatol. 1997 Aug;137(2):234-40.
Fullerton A, et al. Characterization of irritant patch test reactions to topical D vitamins and all-trans retinoic acid in comparison with sodium lauryl sulphate. Evaluation by clinical scoring and multiparametric non-invasive measuring techniques. Br J Dermatol. 1997 Aug;137(2):234-40.
Stio M, et al. Interaction among vitamin D(3) analogue KH 1060, TNF-alpha, and vitamin D receptor protein in peripheral blood mononuclear cells of inflammatory bowel disease patients. Int Immunopharmacol. 2006 Jul;6(7):1083-92. Epub 2006 Feb 23.
Stio M, et al. Interaction among vitamin D(3) analogue KH 1060, TNF-alpha, and vitamin D receptor protein in peripheral blood mononuclear cells of inflammatory bowel disease patients. Int Immunopharmacol. 2006 Jul;6(7):1083-92. Epub 2006 Feb 23.
Shimizu T, et al. Synergistic induction of gene expression during the differentiation into mature macrophage in human myeloblastic leukemia cells treated with TPA and KH1060.Leuk Res. 2009 Jun;33(6):803-9. Epub 2009 Jan 13.
Shimizu T, et al. Synergistic induction of gene expression during the differentiation into mature macrophage in human myeloblastic leukemia cells treated with TPA and KH1060.Leuk Res. 2009 Jun;33(6):803-9. Epub 2009 Jan 13.

Other Notes

Small volumes of Lexacalcitol, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Lexacalcitol purchase

MBS5755095 is an inhibitor targeting Lexacalcitol.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000